UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.87+1.77 (+6.30%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma r&d expenses
Research and development expenses are spending on new products and technology.
UroGen Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $61.26M, down 5.8% year over year. For fiscal 2025 it was $67.11M, up 17.4% from the year before. The highest annual figure on record is $67.11M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.11M | +17.4% |
| FY2024 | Dec 31, 2024 | $57.15M | +25.3% |
| FY2023 | Dec 31, 2023 | $45.61M | -13.8% |
| FY2022 | Dec 31, 2022 | $52.91M | +11.0% |
| FY2021 | Dec 31, 2021 | $47.64M | +0.7% |
| FY2020 | Dec 31, 2020 | $47.31M | -4.0% |
| FY2019 | Dec 31, 2019 | $49.30M | +33.5% |
| FY2018 | Dec 31, 2018 | $36.93M | +97.5% |
| FY2017 | Dec 31, 2017 | $18.70M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.34M | -8.3% |
| Q1 FY2026 | Mar 31, 2026 | $15.60M | -21.5% |
| Q4 FY2025 | Dec 31, 2025 | $14.31M | -3.9% |
| Q3 FY2025 | Sep 30, 2025 | $14.01M | +23.4% |
| Q2 FY2025 | Jun 30, 2025 | $18.91M | +22.8% |
| Q1 FY2025 | Mar 31, 2025 | $19.87M | +28.2% |
| Q4 FY2024 | Dec 31, 2024 | $14.89M | +31.8% |
| Q3 FY2024 | Sep 30, 2024 | $11.36M | +11.0% |
| Q2 FY2024 | Jun 30, 2024 | $15.40M | +33.0% |
| Q1 FY2024 | Mar 31, 2024 | $15.49M | +24.0% |
| Q4 FY2023 | Dec 31, 2023 | $11.30M | -21.9% |
| Q3 FY2023 | Sep 30, 2023 | $10.23M | -21.9% |
| Q2 FY2023 | Jun 30, 2023 | $11.58M | -8.4% |
| Q1 FY2023 | Mar 31, 2023 | $12.50M | -1.6% |
| Q4 FY2022 | Dec 31, 2022 | $14.48M | +10.7% |
| Q3 FY2022 | Sep 30, 2022 | $13.09M | +9.8% |
| Q2 FY2022 | Jun 30, 2022 | $12.64M | +4.3% |
| Q1 FY2022 | Mar 31, 2022 | $12.70M | +20.8% |
| Q4 FY2021 | Dec 31, 2021 | $13.08M | +5.5% |
| Q3 FY2021 | Sep 30, 2021 | $11.92M | +16.8% |
| Q2 FY2021 | Jun 30, 2021 | $12.12M | +49.6% |
| Q1 FY2021 | Mar 31, 2021 | $10.51M | -36.6% |
| Q4 FY2020 | Dec 31, 2020 | $12.41M | -38.3% |
| Q3 FY2020 | Sep 30, 2020 | $10.21M | +7.7% |
| Q2 FY2020 | Jun 30, 2020 | $8.11M | -18.9% |
| Q1 FY2020 | Mar 31, 2020 | $16.59M | +70.6% |
| Q4 FY2019 | Dec 31, 2019 | $20.09M | +75.3% |
| Q3 FY2019 | Sep 30, 2019 | $9.48M | -1.0% |
| Q2 FY2019 | Jun 30, 2019 | $10.00M | +20.8% |
| Q1 FY2019 | Mar 31, 2019 | $9.73M | +27.6% |
| Q4 FY2018 | Dec 31, 2018 | $11.47M | +69.6% |
| Q3 FY2018 | Sep 30, 2018 | $9.57M | +70.3% |
| Q2 FY2018 | Jun 30, 2018 | $8.27M | +126.6% |
| Q1 FY2018 | Mar 31, 2018 | $7.62M | +186.1% |
| Q4 FY2017 | Dec 31, 2017 | $6.76M | – |
| Q3 FY2017 | Sep 30, 2017 | $5.62M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.65M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.66M | – |
See a number that looks wrong?